2025 North America Biologics Safety Testing Market Revenue Opportunities Report
Description
The 2025 North America Biologics Safety Testing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biologics Safety Testing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biologics safety testing market in North America include Thermo Fisher Scientific Inc., Charles River Laboratories, Merck KGaA, and SGS Société Générale de Surveillance SA. Thermo Fisher Scientific is a leading global technology company providing analytical instruments, reagents, and services, focusing on expanding biosafety testing capabilities including new GMP lab services in North America. Charles River Laboratories is a key player known for comprehensive biological safety testing services supporting biopharmaceutical development and regulatory compliance. Merck KGaA has recently invested in a $328 million biosafety testing facility in Maryland, strengthening its analytical and safety capabilities for innovative drugs. SGS North America operates a network of contract laboratories with advanced biologics testing services at its Lincolnshire, Illinois site, supporting small and large molecule product safety from early cell bank assessment to final product release.
These companies dominate the North American biologics safety testing market driven by robust biopharmaceutical industry growth, stringent FDA regulations, and rising R&D investments. North America holds over 36% of the global market share, fueled by demand for biologics safety testing due to increasing chronic disease prevalence and innovation in biologics, vaccines, and gene therapies. Their extensive laboratory networks and investments in new technology and facilities enable comprehensive testing such as endotoxin, sterility, cell line authentication, and residual contaminant detection, ensuring compliance with regulatory standards and accelerating drug development timelines.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biologics Safety Testing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biologics safety testing market in North America include Thermo Fisher Scientific Inc., Charles River Laboratories, Merck KGaA, and SGS Société Générale de Surveillance SA. Thermo Fisher Scientific is a leading global technology company providing analytical instruments, reagents, and services, focusing on expanding biosafety testing capabilities including new GMP lab services in North America. Charles River Laboratories is a key player known for comprehensive biological safety testing services supporting biopharmaceutical development and regulatory compliance. Merck KGaA has recently invested in a $328 million biosafety testing facility in Maryland, strengthening its analytical and safety capabilities for innovative drugs. SGS North America operates a network of contract laboratories with advanced biologics testing services at its Lincolnshire, Illinois site, supporting small and large molecule product safety from early cell bank assessment to final product release.
These companies dominate the North American biologics safety testing market driven by robust biopharmaceutical industry growth, stringent FDA regulations, and rising R&D investments. North America holds over 36% of the global market share, fueled by demand for biologics safety testing due to increasing chronic disease prevalence and innovation in biologics, vaccines, and gene therapies. Their extensive laboratory networks and investments in new technology and facilities enable comprehensive testing such as endotoxin, sterility, cell line authentication, and residual contaminant detection, ensuring compliance with regulatory standards and accelerating drug development timelines.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
